Esperion Therapeutics, Inc.

Contributing Author

Recent Articles by Esperion Therapeutics, Inc.

Aug-29	Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias ESPR GlobeNewswire
Aug-26	Esperion to Participate in Upcoming September Investor Conferences ESPR GlobeNewswire
Aug-07	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ESPR GlobeNewswire
Aug-05	Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update ESPR GlobeNewswire
Jul-22	Esperion to Report Second Quarter 2025 Financial Results on August 5 ESPR GlobeNewswire
Jul-08	Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 ESPR GlobeNewswire
Jul-01	Esperion Appoints Craig Thompson to Board of Directors ESPR GlobeNewswire
Jun-02	Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 ESPR GlobeNewswire
May-20	Esperion to Participate in Upcoming June Investor Conferences ESPR GlobeNewswire
May-12	Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 ESPR GlobeNewswire
May-09	Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference ESPR GlobeNewswire
May-08	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ESPR GlobeNewswire
May-08	Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada ESPR GlobeNewswire
May-06	Esperion Reports First Quarter 2025 Financial Results ESPR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.